The Value of Stillness
Health Care: Drugs
Regulus Therapeutics Inc (RGLS: NASDAQ)
$9.90 0.03 | 0.30%
06/18/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 9.87 |
| 52 Week High | 10.20 |
| 52 Week Low | 4.02 |
| Avg. Daily Vol. (Mil) | 0.08 |
| Beta (3 year) | 0.00 |
| Share Related Items | |
| Mkt Cap (Mil) | 355.39 |
| Shares Out (Mil) | 36.01 |
| Float (Mil) | 6.27 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 7.10 |
| Current Ratio | 7.20 |
| LT Debt/ Equity | 0.21 |
| Total Debt / Equity | 0.21 |
| Valuation Ratios | |
| Price Earnings | 0.40 |
| Price/Sales | 38.28 |
| Price/Book | 6.36 |
| Price/Cash Flow | -19.60 |
| Per Share Data | |
| Earnings | 22.73 |
| Sales | 0.26 |
| Book Value | 1.55 |
| Cash Flow | -0.50 |
| Business Summary | |
|---|---|
| Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. | |
| General Information | |
| 3545 John Hopkins Court
Suite 210 San Diego, CA 92121 |
|
| http;//www.regulusrx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 71 | |
| CEO: Dr. Kleanthis G. Xanthop | |
| Short Interest | |
| Current Month (Mil) | 0.41 |
| Previous Month (Mil) | 0.42 |
| Short Interest Ratio (Days) | 5.40 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -20.40 |
| Return on Investments | -29.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with RGLS
- Portfolio NameUser Type
Latest RGLS Headlines from TheStreet
- 8 Stocks Roaring Higher on Unusual Volume 12.27.12 | 03:12 pm
- Cramer's 'Mad Money' Recap: Focus on What Matters 10.15.12 | 07:10 pm
- IPOs: LifeLock, Luxfer, Regulus
10.02.12 | 06:10 am
Press Releases for RGLS
- Zosano Pharma, Inc. Expands Board Of Directors With Addition Of Kleanthis G. Xanthopoulos, Ph.D. - PR Newswire 04.15.13 | 11:04 am
- Regulus Appoints William H. Rastetter, Ph.D. To Its Board Of Directors - PR Newswire 04.01.13 | 08:04 am
- Regulus To Present At Future Leaders In The Biotech Industry Conference - PR Newswire 03.28.13 | 04:03 pm
- Regulus To Present At Cowen And Company 33rd Annual Healthcare Conference - PR Newswire 02.26.13 | 04:02 pm
- Regulus Announces Timing For Fourth Quarter And Year-End 2012 Financial Results Webcast And Conference Call - PR Newswire 02.13.13 | 04:02 pm
- Regulus To Present At Two Upcoming Investor Conferences - PR Newswire 02.04.13 | 04:02 pm
- Regulus Appoints Mark G. Foletta To Its Board Of Directors - PR Newswire 01.31.13 | 08:01 am
- Regulus To Present At 31st Annual J.P. Morgan Healthcare Conference - PR Newswire 01.03.13 | 04:01 pm
- Regulus Announces Addition To Russell 2000 Index - PR Newswire 12.20.12 | 08:12 am
- Regulus To Host NASDAQ Closing Bell Ceremony On December 5, 2012 - PR Newswire 12.03.12 | 08:12 am
Partner Headlines for RGLS
- UPDATE: Wedbush Securities Initiates Regulus Therapeutics at Outperform on Pipeline Progress - Benzinga 11.29.12 | 01:11 pm
- Regulus Therapeutics: Serious Red Flags At This Public Offering - Seeking Alpha 10.08.12 | 09:10 am
- Six More IPOs this Week - NASDAQ 10.05.12 | 09:10 pm
